Janux Therapeutics vs Precigen
Janux Therapeutics and Precigen are similar in size: $10.0m and $9.7m of revenue in their latest fiscal years. Precigen grew faster (146.7% against -5.6%). Janux Therapeutics kept more of each dollar of sales as profit: a net margin of -1136.3% against -2588.2%. Janux Therapeutics carries less debt relative to equity (0.0% against 478.2%).
| Latest fiscal year | Janux TherapeuticsJANX, 2025 | PrecigenPGEN, 2025 |
|---|---|---|
| Revenue | $10.0m | $9.7m |
| Revenue growth | -5.6% | 146.7% |
| Net income | −$114m | −$251m |
| Operating margin | -1576.7% | -1141.1% |
| Net margin | -1136.3% | -2588.2% |
| Return on equity | -11.5% | — |
| Free cash flow | −$83.3m | −$89.8m |
| Cash | $52.3m | $30.2m |
| Total debt | $0 | $100m |
| Debt to equity | 0.0% | 478.2% |
| Dividend per share | — | — |
| Dividend yield | — | — |
| Share buybacks | — | — |
| Employees | 109 | — |
| Market value | $1.08bn | $1.84bn |
| Price vs our value range | — | — |
| Moat score | 12 (Weak) | 9 (Weak) |
| Insider trades, 12 months | 0 buys, 11 sales | 1 buys, 40 sales |